Identifying the bottlenecks that are preventing effective management of neovascular AMD.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration
The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Patients with high genetic risk of AMD should avoid instant coffee, investigators say
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.